-
Posted by
Two Blokes Jul 1 -
Filed in
Stock
-
5 views
AstraZeneca's price performance YTD exceeds the healthcare sector and broader markets, indicating investors are assuaged regarding concerns across geographies. The company has offered greater clarity on why its under investigation in China, and so far there's reason to believe matters are under control. US tariffs are unlikely to affect its financials significantly in 2025 either, with the company assuring that only a minority of treatments are imported into the market.
